Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (181-190 of 223) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Blood|October 17, 2015
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaSusan M O'Brien, Nicole Lamanna, Thomas J Kipps, et al.
Blood Advances|March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
American Journal of Hematology|February 16, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisSusan M O'Brien, John C Byrd, Peter Hillmen, et al.
Haematologica|August 16, 2019
A cross-trial comparison of single-agent ibrutinib <i>versus</i> chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaAlessandra Tedeschi, Richard Greil, Fatih Demirkan, et al.
Blood|June 25, 2017
Tonic B-cell receptor signaling in diffuse large B-cell lymphomaOndrej Havranek, Jingda Xu, Stefan Köhrer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.
The Lancet. Oncology|August 25, 2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyJan A Burger, Michael J Keating, William G Wierda, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
Pageof 23

Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Blood|October 17, 2015
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaSusan M O'Brien, Nicole Lamanna, Thomas J Kipps, et al.
Blood Advances|March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
American Journal of Hematology|February 16, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisSusan M O'Brien, John C Byrd, Peter Hillmen, et al.
Haematologica|August 16, 2019
A cross-trial comparison of single-agent ibrutinib <i>versus</i> chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaAlessandra Tedeschi, Richard Greil, Fatih Demirkan, et al.
Blood|June 25, 2017
Tonic B-cell receptor signaling in diffuse large B-cell lymphomaOndrej Havranek, Jingda Xu, Stefan Köhrer, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.
The Lancet. Oncology|August 25, 2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyJan A Burger, Michael J Keating, William G Wierda, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
Pageof 23